Vancouver-based CereCura Nanotherapeutics, a University of British Columbia (UBC) spinout, has secured $1.4 million CAD in seed funding to advance a new approach for treating neurological diseases using lipid nanoparticle (LNP) RNA technology—the same delivery platform that enabled Moderna and Pfizer’s COVID-19 vaccines.